Fig. 1From: The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patientsProgression-free survival according to CEA, CYFRA21-1 and NSE reduction ≥ 20%Back to article page